102 related articles for article (PubMed ID: 21658766)
1. Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens.
Blanco B; Sánchez-Abarca LI; Caballero-Velázquez T; Santamaría C; Inogés S; Pérez-Simón JA
Leuk Res; 2011 Oct; 35(10):1412-5. PubMed ID: 21658766
[TBL] [Abstract][Full Text] [Related]
2. Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings.
Davies JK; Koh MB; Lowdell MW
Biol Blood Marrow Transplant; 2004 Apr; 10(4):259-68. PubMed ID: 15077224
[TBL] [Abstract][Full Text] [Related]
3. In vitro methotrexate as a practical approach to selective allodepletion.
Sathe A; Ortega SB; Mundy DI; Collins RH; Karandikar NJ
Biol Blood Marrow Transplant; 2007 Jun; 13(6):644-54. PubMed ID: 17531774
[TBL] [Abstract][Full Text] [Related]
4. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering.
Nonn M; Herr W; Khan S; Todorova M; Link I; Thies J; Distler E; Kaltwasser M; Hoffmann J; Huber C; Hartwig UF
Transplantation; 2008 Nov; 86(10):1427-35. PubMed ID: 19034014
[TBL] [Abstract][Full Text] [Related]
5. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibitor clioquinol as a candidate drug in prophylaxis and treatment of acute graft-versus-host disease.
Liang Y; Mao X; Liu H
Med Hypotheses; 2011 Mar; 76(3):400-2. PubMed ID: 21122999
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
9. Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes.
Hartwig UF; Nonn M; Khan S; Meyer RG; Huber C; Herr W
Bone Marrow Transplant; 2006 Feb; 37(3):297-305. PubMed ID: 16327814
[TBL] [Abstract][Full Text] [Related]
10. Selective depletion strategies in allogeneic stem cell transplantation.
Mielke S; Solomon SR; Barrett AJ
Cytotherapy; 2005; 7(2):109-15. PubMed ID: 16040390
[TBL] [Abstract][Full Text] [Related]
11. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis.
Koh MB; Prentice HG; Lowdell MW
Bone Marrow Transplant; 1999 May; 23(10):1071-9. PubMed ID: 10373075
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.
Sun K; Welniak LA; Panoskaltsis-Mortari A; O'Shaughnessy MJ; Liu H; Barao I; Riordan W; Sitcheran R; Wysocki C; Serody JS; Blazar BR; Sayers TJ; Murphy WJ
Proc Natl Acad Sci U S A; 2004 May; 101(21):8120-5. PubMed ID: 15148407
[TBL] [Abstract][Full Text] [Related]
13. The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses.
Yanaba K; Yoshizaki A; Muroi E; Hara T; Ogawa F; Shimizu K; Sato S
J Leukoc Biol; 2010 Jul; 88(1):117-22. PubMed ID: 20418448
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines.
Blanco B; Pérez-Simón JA; Sánchez-Abarca LI; Carvajal-Vergara X; Mateos J; Vidriales B; López-Holgado N; Maiso P; Alberca M; Villarón E; Schenkein D; Pandiella A; San Miguel J
Blood; 2006 May; 107(9):3575-83. PubMed ID: 16282346
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of cyclosporin A on the alloreactivity of fresh and ex vivo-expanded T lymphocytes.
Contassot E; Robinet E; Angonin R; Laithier V; Bittencourt M; Pavy JJ; Cahn JY; Hervé P; Tiberghien P
Bone Marrow Transplant; 1998 Dec; 22(11):1097-102. PubMed ID: 9877273
[TBL] [Abstract][Full Text] [Related]
16. Clinical-scale selective depletion of alloreactive T cells using an anti-CD25 immunotoxin.
Michálek J; Collins RH; Vitetta ES
Neoplasma; 2003; 50(4):296-9. PubMed ID: 12937844
[TBL] [Abstract][Full Text] [Related]
17. Improving immune reconstitution while preventing GvHD in allogeneic stem cell transplantation.
André-Schmutz I; Dal Cortivo L; Fischer A; Cavazzana-Calvo M
Cytotherapy; 2005; 7(2):102-8. PubMed ID: 16040389
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib inhibits T-cell function versus infective antigenic stimuli in a dose-dependent manner in vitro.
Orciuolo E; Galimberti S; Petrini M
Leuk Res; 2007 Jul; 31(7):1026-7. PubMed ID: 17045335
[No Abstract] [Full Text] [Related]
19. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.
Lilleri D; Fornara C; Chiesa A; Caldera D; Alessandrino EP; Gerna G
Haematologica; 2008 Feb; 93(2):248-56. PubMed ID: 18245650
[TBL] [Abstract][Full Text] [Related]
20. Progress and prospects: graft-versus-host disease.
Mastaglio S; Stanghellini MT; Bordignon C; Bondanza A; Ciceri F; Bonini C
Gene Ther; 2010 Nov; 17(11):1309-17. PubMed ID: 20508597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
